ArticleTranslational psychiatry2026
mTOR-driven autophagy-inflammation crosstalk underlies schizophrenia pathophysiology.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The NLRP3 inflammasome: pathophysiology and therapeutic implications for schizophrenia and neuropsychiatric disorders.Molecular psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Schizophrenia (SZ) is characterized by immune dysregulation and decreased autophagy. However, the mechanistic interplay between these two processes remains unclear. This study aimed to explore the relationship between autophagy and inflammation in SZ patients and a maternal immune activation (MIA)-induced SZ mouse model. Autophagic activity and inflammatory markers were assessed in peripheral blood mononuclear cells (PBMCs) from SZ patients and healthy controls using flowcytometry, Western blotting, and qPCR. Cytokine modulation experiments were conducted in vitro to determine causal relationships. Behavioral, molecular, and neurochemical analyses were performed in MIA-induced SZ-like mice, with or without mTOR inhibitor rapamycin treatment, to assess the role of mTOR-regulated autophagy in vivo. SZ patients exhibited reduced autophagic-lysosome function in PBMCs, evidenced by decreased monodansylcadaverine-positive cells, Beclin-1, LC3B/LC3A, LAMP1, and cathepsin D, alongside increased p62 levels, accompanied by hyperactivation of the PI3K/AKT/mTOR pathway and ULK1 inhibition. These changes were associated with elevated inflammatory markers, including IL-1β, IL-6, IFN-γ, and NLRP3 inflammasome components (NLRP3, ASC, caspase-1). Pharmacological inhibition of autophagy further amplified inflammatory gene expression in vitro, while IL-10 treatment restored LC3B expression, which suppressed by IL-1β/IL-6. MIA mice showed SZ-like behaviors, reduced hippocampal Beclin-1, glial polarization imbalance, cortical neuroinflammation, and monoaminergic disruptions. Rapamycin-induced mTOR inhibition restored autophagy and reversed these abnormalities. Our findings demonstrated that hyperactivation of mTOR suppressed autophagy, leading to sustained elevation of pro-inflammatory cytokines in SZ. Inhibition of mTOR restored autophagic activity, thereby reducing neuroinflammation and glial pro-inflammatory activation, suggesting autophagy as a promising therapeutic target for SZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.